Dataset Information

One-Year Hemodynamic Performance of Three Cardiac Aortic Bioprostheses: A Randomized Comparative Clinical Trial.

ABSTRACT:

Background

We aimed to compare 1 year the hemodynamic in-vivo performance of three biological aortic prostheses (Carpentier Perimount Magna Ease^TM, Crown PRT^TM, and Trifecta^TM).

Methods

The sample used in this study comes from the "BEST-VALVE" clinical trial, which is a phase IV single-blinded randomized clinical trial with the three above-mentioned prostheses.

Results

154 patients were included. Carpentier Perimount Magna Ease^TM (n = 48, 31.2%), Crown PRT^TM (n = 51, 32.1%) and Trifecta^TM (n = 55, 35.7%). One year after the surgery, the mean aortic gradient and the peak aortic velocity was 17.5 (IQR 11.3-26) and 227.1 (IQR 202.0-268.8) for Carpentier Perimount Magna Ease^TM, 21.4 (IQR 14.5-26.7) and 237.8 (IQR 195.9-261.9) for Crown PRT^TM, and 13 (IQR 9.6-17.8) and 209.7 (IQR 176.5-241.4) for Trifecta^TM, respectively. Pairwise comparisons demonstrated improved mean gradients and maximum velocity of Trifecta^TM as compared to Crown PRT^TM. Among patients with nominal prosthesis sizes ≤ 21, the mean and peak aortic gradient was higher for Crown PRT^TM compared with Trifecta^TM, and in patients with an aortic annulus measured with metric Hegar dilators less than or equal to 22 mm.

Conclusions

One year after surgery, the three prostheses presented a different hemodynamic performance, being Trifecta^TM superior to Crown PRT^TM.

SUBMITTER: Montero-Cruces L

PROVIDER: S-EPMC8625181 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundBioprosthesis has been increasingly implanted for the treatment of transvalvular disease across the world. A new Dafodil™ pericardial bioprosthesis (Meril Life Sciences Pvt. Ltd., India) recently approved by Conformité Européenne (CE) is a tri-leaflet, stented, bovine valve. The purpose of Dafodil-1 first-in-human trial was to evaluate clinical safety and performance (including hemodynamic parameters) of the Dafodil pericardial bioprosthesis in patients who underwent aortic or mitral valve replacement.MethodsThis prospective, multicenter clinical trial enrolled 60 patients (Aortic: 30 patients; Mitral: 30 patients) from seven sites across India. Safety endpoints were early (?30?days) and late (>?30?days) mortality and valve-related morbidity. The performance endpoints were hemodynamic performance, improvement in NYHA functional class, and change in the quality of life using SF-12v1 health survey.ResultsFrom July 2017 to July 2018, 60 patients underwent implantation of the Dafodil pericardial bioprosthesis. Post-operatively, NYHA functional class significantly improved in all the patients (Aortic: 90% NYHA class-I and 10% NYHA class-II; Mitral: 96.55% NYHA class-I and 3.45% NYHA class-II; P?<?0.001). There was no death in aortic valve replacement patients till 12-month. In mitral valve replacement patients, early mortalities occurred in three patients, and late mortality occurred in one patient; none of these were valve-related. Freedom from all-cause mortality reported was 93.33% at 12-month. Mean aortic pressure gradient decreased from 52.71?±?24.47?mmHg [with 0.89?±?0.70?cm2 effective orifice area (EOA)] pre-operatively to 14.49?±?6.58?mmHg (EOA: 1.85?±?0.27?cm2) at 12-month. Overall, the mitral mean pressure gradient and EOA were 4.41?±?1.69?mmHg and 2.67?±?0.48?cm2, respectively, at 12-month. Significant improvement (P?<?0.05) in the patients’ quality of life was reported at all follow-ups.ConclusionsThe clinical safety and performance of the Dafodil pericardial bioprosthesis were favourable at 12-month. Moreover, a study with a larger patient population and longer follow-up is warranted to further assess the device.Trial registrationDafodil-1 trial has been prospectively registered on 10/07/2017 under Clinical Trial Registry-India (http://www.ctri.nic.in). (Registration number: CTRI/2017/07/009008).